Background & aim: Aims: Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function…
Background & aim: Conventional methods for assessing skeletal muscle remodelling, including lean mass, muscle weight, and histology, lack the spatial resolution and sensitivity to capture three-dimensional muscle architecture. Here, we developed a scalable, non-destructive, AI-enabled light-sheet fluorescence microscopy (LSFM) platform…
Background & aim: Efficient delivery of anti-β-amyloid (Aβ) antibodies across the blood–brain barrier (BBB) remains a central challenge in Alzheimer’s disease (AD) therapy. Therapeutic Aβ-targeted antibodies engineered for receptor-mediated transcytosis display improved brain exposure and therapeutic efficacy, yet their brain-wide…
Background & aim: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation of neuroinflammation. However, the cellular mechanisms underlying GLP-1RA effects on neuroinflammation remain poorly…
Background & aim: Chronic myocardial injury over weeks to months drives cellular hypertrophy and extracellular matrix remodeling, culminating in heart failure with preserved ejection fraction (HFpEF). Traditional 2D histological sectioning may miss or misrepresent the true spatial heterogeneity of localized…
Background & aim: Translational models are essential to identify improved treatment options for chronic kidney disease (CKD) patients. However, most preclinical CKD models do not demonstrate reduced glomerular filtration rate (GFR) or improvement by standard of care (SoC). The aim…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunctionassociated steatohepatitis (MASH). Efruxifermin (EFX) is a long acting FGF21 analogue currently in phase 3…
Background & aim: The long-acting glucagon-like peptide-1 (GLP1) receptor agonist semaglutide was recently approved as the first GLP-1–based therapy for people with MASH and moderate-to-severe fibrosis. Clinical studies have demonstrated that semaglutide not only improves liver histology but also reverses…
